Testing bortezomib with temozolomide for grade-4 glioma that has come back
Original title: Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17)
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people to see if the drug pair is safe.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests two drugs given together in people whose grade-4 brain tumor has returned.
Who this trial is for. This trial is for people with a grade-4 glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary that has come back, and whose tumor has an unmethylated MGMT promoter. It tests the drugs bortezomib and temozolomide given together on a set schedule.
Where it stands. There are no results yet. The trial is checking how safe this drug pair is, and whether it helps people live longer. Those answers are not in yet. The source does not report any findings.
What this means, and what it doesn't
What it could mean: Right now this tells us nothing about whether the drug pair works. It is a study, not care your own doctor can give you. If your tumor is a grade-4 glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary that has come back, you could ask your care team whether a trial like this is worth looking into for you.
What it doesn't mean: This does not mean the treatment works. A trial is a test of an idea, not a proven treatment. Joining a trial is not a guarantee that you will be helped, and some people are not helped at all. This is not a promise of a cure. It is also not a promise that you can join. The trial team decides who fits.
Source: ClinicalTrials.gov, August 4, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.